Fig. 3From: Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging studya Mean (SD) LVM over time; b mean (SD) change from baseline in LVM over time (Phase 2 study; safety population). Vertical bars show SD. LVM left ventricular mass, SD standard deviationBack to article page